A study of the capability of manufacturers of generic hormonal contraceptives in lower- and middle-income countries

Contraception

Volumn 75, Issue 4, 2007, Pages 311-317

  Hall, Peter E ^a,b,c,d   Oehler, Joachim ^a   Woo, Phillip ^a   Zardo, Humberto ^a   Chinery, Lester ^b   Singh, Jyoti S ^c   Jooseery, S Harry ^c   Essah, Nana M ^d  

^a Concept Foundation ^*  (Thailand)

^b International Planned Parenthood Federation ^*  (United Kingdom)

^c Partners in Population and Development   (Bangladesh)

^d UNITED NATIONS POPULATION FUND   (United States)

Author keywords

cGMP; Generic; Hormonal contraceptives; Manufacture; Prequalification

Indexed keywords

CONTRACEPTIVE AGENT; GENERIC DRUG; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; POSTCOITUS CONTRACEPTIVE AGENT;

ARTICLE; DEVELOPING COUNTRY; DOCUMENTATION; DRUG MANUFACTURE; EMERGENCY CONTRACEPTION; ENVIRONMENTAL PROTECTION; GOOD MANUFACTURING PRACTICE; HORMONAL CONTRACEPTION; OCCUPATIONAL SAFETY; ORAL CONTRACEPTION; PILL; PROFESSIONAL COMPETENCE; QUALITATIVE RESEARCH; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; STAFF; TABLET; TOTAL QUALITY MANAGEMENT; WORLD HEALTH ORGANIZATION;

CONTRACEPTIVE AGENTS, FEMALE; DEVELOPING COUNTRIES; DRUG INDUSTRY; DRUGS, GENERIC; FEMALE; HUMANS; LEVONORGESTREL; MEDROXYPROGESTERONE 17-ACETATE;

EID: 33947108455     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.11.008     Document Type: Article

References (6)

1. United Nations Population Fund. Reproductive health essentials - securing the supply: global strategy for reproductive health commodity security (2002), UNFPA, New York. http://www.unfpa.org/publications/detail.cfm?ID=27&filterListType= See www.unfpa.org/publications/detail.cfm?ID=27&filterListType= [accessed 1 October 2006]
2. Reproductive Health Supplies Coalition, 2006. See. http://www.rhsupplies.org/coalition.shtml?navid=15 [accessed 1 October 2006]
3. Hall P.E. What has been achieved, what have been the constraints and what are the future priorities for pharmaceutical product-related R&D to the reproductive health needs of developing countries? Commission on Intellectual Property Rights, Innovation and Public Health, Geneva: World Health Organization, 2005. See. http://www.who.int/intellectualproperty/studies/reproductive_health/en/i ndex.html [accessed 1 October 2006]
4. World Health Organization. The 14th model list of essential medicines, March 2005 (2005), World Health Organization, Geneva
5. World Health Organization. The interagency list of essential medicines for reproductive health, 2006, WHO, International Planned Parenthood Federation, John Snow Inc, Population Services International, United Nations Population Fund, World Bank. Geneva: World Health Organization, 2006. WHO/PSM/PAR/2006.1, WHO/RHR/2006.1.
6. World Health Organization. WHO's programme for the prequalification of medicines (2006), WHO, Geneva. http://mednet3.who.int/prequal/ See http://mednet3.who.int/prequal/ [accessed 16 October 2006]